Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Business Wire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Cash runway into 2029 backed by $694 million cash and $288 million October financing
- ➤Casdatifan second-line Phase 3 enrollment expected to complete within two to three months
- ➤PEAK-20 first-line Phase 3 study expected to initiate by year-end 2026
- ➤Casdatifan late-line monotherapy delivered 35-month median overall survival and 36% response rate
- ➤Third-quarter revenue fell to $9 million while net loss narrowed to $128 million
Expert Statements
Terry Rosen, Chief Executive Officer of Arcus Biosciences
“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”
Terry Rosen, Chief Executive Officer of Arcus Biosciences
“With PEAK-1 enrollment nearing completion and PEAK-20 set to begin by year-end, we are building the registrational evidence to make casdatifan the backbone of treatment across the continuum of care for clear cell renal cell carcinoma.”
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
* ARC-20 data presented in October demonstrated the extraordinary opportunity for casdatifan to be a backbone treatment across every line of kidney cancer therapy
Get started
Create a free account to read the full story.